Email ID
Password
Therapy Sector - Other
JOB OF THE WEEK Promote your vacancy here
The US FDA was established in 1931, but only three years ago did it get the power to order drug makers to conduct safety studies of products that have already been approved and put into general use. Just how difficult it is going to be to use that ...
The US FDA has announced an "ongoing safety review" of oral bisphosphosphonates to see if they are potentially linked to atypical subtrochanteric femur fractures, or fractures in the bone just below the hip joint. For the data reviewed to date, ...
PTC Therapeutics and Genzyme 's ataluren, an experimental nonsense mutation suppressor, has failed in nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD), show top-line Phase IIb results. Around 10-15% of DBMD cases are due to nonsense ...
Development of Roche and Biogen Idec 's humanised anti-CD20 monoclonal antibody ocrelizumab for rheumatoid arthritis (RA) has been halted after patients in clinical trials suffered serious opportunistic infections, some of which were fatal. The drug ...
The Federal Court of Australia has ordered Merck & Co to pay A$287,912 ($259,400) plus interest to a 59 year-old man who suffered a heart attack after taking the arthritis pain relief drug Vioxx (rofecoxib), in the first such trial outside the ...
 
The EU's CHMP has concluded that Janssen-Cilag 's (a Johnson & Johnson subsidiary) treatment for neuropathic skin ulcers in diabetic patients, Regranex (becaplermin), must not be used in patients who ...
The US FDA has issued GlaxoSmithKline and XenoPort a complete response letter for their non-dopaminergic restless legs syndrome (RLS) therapy, Horizant (gabapentin enacarbil extended-release, ...
The US FDA 's drug centre (CDER) had a productive year in 2009, with 25 approvals of novel products, up slightly from the 24 total of 2008. The list shows how much biologics have attracted the ...
 
It has been a bad week for anticancer drug development, with two late-stage projects coming to grief and a third being shelved. First came news that Danish company Genmab ’s head and neck cancer ...
Takara Bio has signed a collaborative research agreement with the University of Pennsylvania in the US for the co-development of an innovative gene-based therapy for HIV. The Japanese firm will work ...
PTC Therapeutics and Genzyme 's ataluren, an experimental nonsense mutation suppressor, has failed in nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD), show top-line Phase IIb results. ...
 
Development of Roche and Biogen Idec 's humanised anti-CD20 monoclonal antibody ocrelizumab for rheumatoid arthritis (RA) has been halted after patients in clinical trials suffered serious ...
Earlier this week, a court in Atlantic City, New Jersey ordered Roche to pay $25,159,530 in damages to an Alabama man who developed severe bowel disease after taking the company’s acne treatment, ...
Roche has reported an 8% rise in 2009 sales to CHF49.1 billion ($46.6 billion), driven by sales of its influenza treatment Tamiflu (oseltamivir), its cancer portfolio and the age-related macular ...
 
Pfizer is facing more disappointment with the development of some of its most advanced anticancers after Sutent (sunitinib) failed two more Phase III trials in advanced breast cancer - ending ...
Roche 's Avastin (bevacizumab), the world's best-selling cancer drug, has failed to prolong overall survival in its only Phase III trial in advanced prostate cancer, CALGB 90401, which was sponsored ...
Shionogi has locked up global rights to QuatRx Pharmaceuticals' lead development project in a deal which could eventually be worth more than $125 million to the private US firm. The Japanese company ...
 
The US FDA 's drug centre (CDER) had a productive year in 2009, with 25 approvals of novel products, up slightly from the 24 total of 2008. The list shows how much biologics have attracted the ...
Novartis 's immunosuppressant Myfortic (mycophenolic acid sodium 180mg/360mg) has been granted orphan status by the Australian Therapeutics Goods Administration (TGA) for the induction and ...
Savient Pharmaceuticals says that it is on track to re-file the BLA seeking an indication in chronic and treatment-failure gout for Krystexxa (pegloticase) in the first quarter of this year. It ...
 
The Philippines government has announced a second wave of price cuts in the medicines sector under the government-mediated access price (GMAP) programme. Most reductions will come into effect on ...
An advisory committee to Japan's ministry of health, labour and welfare has recommended for approval Takeda 's oral antidiabetic, alogliptin. The positive opinion moves the DPP-4 inhibitor closer to ...
NicOx has signed a licensing agreement which grants Bausch & Lomb exclusive worldwide rights to develop and commercialise NCX 116, a nitric oxide-donating prostaglandin F2α-analogue, which has ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36